catalyst.phrma.org
Open in
urlscan Pro
2606:2c40::c73c:67e4
Public Scan
Submitted URL: https://c2zjk04.na1.hubspotlinks.com/Ctc/48+113/c2ZjK04/VWBs3C65DXjpW27T7zn2x1xVrW11fj5c4XBh2sN6-TN-D5R157V3Zsc37CgDS0N8g9rrYp-j2SW3K...
Effective URL: https://catalyst.phrma.org/icymi-cancer-death-rate-continues-to-decline-due-to-treatment-advances?utm_medium=email&_hsenc=p...
Submission: On February 28 via manual from US — Scanned from DE
Effective URL: https://catalyst.phrma.org/icymi-cancer-death-rate-continues-to-decline-due-to-treatment-advances?utm_medium=email&_hsenc=p...
Submission: On February 28 via manual from US — Scanned from DE
Form analysis 4 forms found in the DOM
POST http://www.phrma.org/search?incmode=keywordsearch&keyword=
<form id="topsearchform" method="post" action="http://www.phrma.org/search?incmode=keywordsearch&keyword=" data-hs-cf-bound="true">
<input type="text" id="tsffield" placeholder="Keyword Search">
<button type="submit" id="tsfbtn"><i class="fa fa-learn-more"></i></button>
</form>GET http://www.phrma.org/search
<form method="get" action="http://www.phrma.org/search" id="sbsearchform" data-hs-cf-bound="true">
<input id="sbffield" type="text" name="keyword">
<button type="submit" id="sbfbtn">Search Now <i class="fa fa-learn-more"></i></button>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/464546/c85fb33b-c094-4800-8f1b-1ca1630341ad
<form id="hsForm_c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" method="POST" accept-charset="UTF-8" enctype="multipart/form-data" novalidate=""
action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/464546/c85fb33b-c094-4800-8f1b-1ca1630341ad"
class="hs-form-private hsForm_c85fb33b-c094-4800-8f1b-1ca1630341ad hs-form-c85fb33b-c094-4800-8f1b-1ca1630341ad hs-form-c85fb33b-c094-4800-8f1b-1ca1630341ad_4f5109ba-4069-41b2-ba37-9e2b24a60907 hs-form stacked"
target="target_iframe_c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" data-instance-id="4f5109ba-4069-41b2-ba37-9e2b24a60907" data-form-id="c85fb33b-c094-4800-8f1b-1ca1630341ad" data-portal-id="464546" data-hs-cf-bound="true">
<fieldset class="form-columns-1">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field"><label id="label-email-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="" placeholder="Enter your Business Email"
for="email-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549"><span>Business Email</span><span class="hs-form-required">*</span></label>
<legend class="hs-field-desc" style="display: block;">Many free email providers not supported (ie yahoo, hotmail, etc)</legend>
<div class="input"><input id="email-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" name="email" required="" placeholder="Business email recommended" type="email" class="hs-input" inputmode="email" autocomplete="email" value=""></div>
</div>
</fieldset>
<fieldset class="form-columns-2">
<div class="hs_firstname hs-firstname hs-fieldtype-text field hs-form-field"><label id="label-firstname-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="" placeholder="Enter your First Name"
for="firstname-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549"><span>First Name</span><span class="hs-form-required">*</span></label>
<legend class="hs-field-desc" style="display: none;"></legend>
<div class="input"><input id="firstname-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" name="firstname" required="" placeholder="" type="text" class="hs-input" inputmode="text" autocomplete="given-name" value=""></div>
</div>
<div class="hs_lastname hs-lastname hs-fieldtype-text field hs-form-field"><label id="label-lastname-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="" placeholder="Enter your Last Name"
for="lastname-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549"><span>Last Name</span><span class="hs-form-required">*</span></label>
<legend class="hs-field-desc" style="display: none;"></legend>
<div class="input"><input id="lastname-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" name="lastname" required="" placeholder="" type="text" class="hs-input" inputmode="text" autocomplete="family-name" value=""></div>
</div>
</fieldset>
<fieldset class="form-columns-1">
<div class="hs_hs_persona hs-hs_persona hs-fieldtype-select field hs-form-field"><label id="label-hs_persona-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="" placeholder="Enter your About You"
for="hs_persona-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549"><span>About You</span><span class="hs-form-required">*</span></label>
<legend class="hs-field-desc" style="display: block;">Which persona best represents you?</legend>
<div class="input"><select id="hs_persona-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" required="" class="hs-input is-placeholder" name="hs_persona">
<option disabled="" value="">- Please Select -</option>
<option value="persona_1">Employed in the BioPharmaceutical Industry</option>
<option value="persona_2">general public</option>
<option value="persona_3">work in health care (non-biopharma)</option>
<option value="persona_4">patient</option>
<option value="persona_5">caregiver or patient organization</option>
<option value="persona_6">government or regulatory agency</option>
<option value="persona_7">credentialed news media</option>
<option value="persona_8">pr/ga/consultant</option>
<option value="persona_9">educational</option>
<option value="persona_10">Investor/Analyst /Financial</option>
</select></div>
</div>
</fieldset>
<fieldset class="form-columns-1">
<div class="hs_blog_default_hubspot_blog_subscription hs-blog_default_hubspot_blog_subscription hs-fieldtype-radio field hs-form-field"><label id="label-blog_default_hubspot_blog_subscription-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class=""
placeholder="Enter your Notification Frequency" for="blog_default_hubspot_blog_subscription-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549"><span>Notification Frequency</span><span class="hs-form-required">*</span></label>
<legend class="hs-field-desc" style="display: block;">How often would you like to receive updates</legend>
<div class="input">
<ul required="" role="checkbox" class="inputs-list multi-container">
<li class="hs-form-radio" role="radio"><label for="blog_default_hubspot_blog_subscription0-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="hs-form-radio-display"><input
id="blog_default_hubspot_blog_subscription0-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="hs-input" type="radio" name="blog_default_hubspot_blog_subscription" value="monthly" checked=""><span>Monthly</span></label></li>
<li class="hs-form-radio" role="radio"><label for="blog_default_hubspot_blog_subscription1-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="hs-form-radio-display"><input
id="blog_default_hubspot_blog_subscription1-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="hs-input" type="radio" name="blog_default_hubspot_blog_subscription" value="weekly"><span>Weekly</span></label></li>
<li class="hs-form-radio" role="radio"><label for="blog_default_hubspot_blog_subscription2-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="hs-form-radio-display"><input
id="blog_default_hubspot_blog_subscription2-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="hs-input" type="radio" name="blog_default_hubspot_blog_subscription" value="instant"><span>Instant</span></label></li>
<li class="hs-form-radio" role="radio"><label for="blog_default_hubspot_blog_subscription3-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="hs-form-radio-display"><input
id="blog_default_hubspot_blog_subscription3-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="hs-input" type="radio" name="blog_default_hubspot_blog_subscription" value="daily"><span>Daily</span></label></li>
</ul>
</div>
</div>
</fieldset>
<fieldset class="form-columns-1">
<div class="hs_zip hs-zip hs-fieldtype-text field hs-form-field"><label id="label-zip-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="" placeholder="Enter your Postal Code" for="zip-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549"><span>Postal
Code</span><span class="hs-form-required">*</span></label>
<legend class="hs-field-desc" style="display: none;"></legend>
<div class="input"><input id="zip-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" name="zip" required="" placeholder="" type="text" class="hs-input" inputmode="text" value=""></div>
</div>
</fieldset>
<fieldset class="form-columns-1">
<div class="hs_lifecyclestage hs-lifecyclestage hs-fieldtype-text field hs-form-field" style="display: none;"><label id="label-lifecyclestage-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" class="" placeholder="Enter your Lifecycle Stage"
for="lifecyclestage-c85fb33b-c094-4800-8f1b-1ca1630341ad_2549"><span>Lifecycle Stage</span></label>
<legend class="hs-field-desc" style="display: none;"></legend>
<div class="input"><input name="lifecyclestage" class="hs-input" type="hidden" value="subscriber"></div>
</div>
</fieldset>
<div class="hs_submit hs-submit">
<div class="hs-field-desc" style="display: none;"></div>
<div class="actions"><input type="submit" class="hs-button primary large" value="Keep Me Updated"></div>
</div><input name="hs_context" type="hidden"
value="{"embedAtTimestamp":"1677620691946","formDefinitionUpdatedAt":"1519144961409","userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/110.0.5481.177 Safari/537.36","pageTitle":"ICYMI: Cancer death rate continues to decline due to treatment advances","pageUrl":"https://catalyst.phrma.org/icymi-cancer-death-rate-continues-to-decline-due-to-treatment-advances?utm_medium=email&_hsenc=p2ANqtz--h0ihUQdW-aD237PzGGqRi-kd3oGXA4DpqJp-IwZJhSaHvRpJ_Pi7ozXzZHI6KLIXUvJRLCdM00mkvd42c9WZLspkfyg&_hsmi=248169804&utm_content=248169804&utm_source=hs_email&hsCtaTracking=30626726-174f-41c2-a6b3-72b3aa372acd%7C179295fd-e41d-4e93-8aca-7a88f9be049c","pageId":"99775113349","urlParams":{"utm_medium":"email","_hsenc":"p2ANqtz--h0ihUQdW-aD237PzGGqRi-kd3oGXA4DpqJp-IwZJhSaHvRpJ_Pi7ozXzZHI6KLIXUvJRLCdM00mkvd42c9WZLspkfyg","_hsmi":"248169804","utm_content":"248169804","utm_source":"hs_email","hsCtaTracking":"30626726-174f-41c2-a6b3-72b3aa372acd|179295fd-e41d-4e93-8aca-7a88f9be049c"},"isHubSpotCmsGeneratedPage":true,"canonicalUrl":"https://catalyst.phrma.org/icymi-cancer-death-rate-continues-to-decline-due-to-treatment-advances","contentType":"blog-post","hutk":"8dcb2186cc321e828ecf3a0dd2d0cbfb","__hsfp":1706262889,"__hssc":"99188225.1.1677620692869","__hstc":"99188225.8dcb2186cc321e828ecf3a0dd2d0cbfb.1677620692869.1677620692869.1677620692869.1","formTarget":"#hs_form_target_blog_subscription_2549","formInstanceId":"2549","pageName":"ICYMI: Cancer death rate continues to decline due to treatment advances","locale":"en","timestamp":1677620692894,"originalEmbedContext":{"portalId":"464546","formId":"c85fb33b-c094-4800-8f1b-1ca1630341ad","region":"na1","target":"#hs_form_target_blog_subscription_2549","isBuilder":false,"isTestPage":false,"formInstanceId":"2549","formsBaseUrl":"/_hcms/forms","css":"","inlineMessage":"Thanks for Subscribing!","isMobileResponsive":true,"pageName":"ICYMI: Cancer death rate continues to decline due to treatment advances","pageId":"99775113349","contentType":"blog-post","formData":{"cssClass":"hs-form stacked"},"isCMSModuleEmbed":true},"correlationId":"4f5109ba-4069-41b2-ba37-9e2b24a60907","renderedFieldsIds":["email","firstname","lastname","hs_persona","blog_default_hubspot_blog_subscription","zip","lifecyclestage"],"captchaStatus":"NOT_APPLICABLE","emailResubscribeStatus":"NOT_APPLICABLE","isInsideCrossOriginFrame":false,"source":"forms-embed-1.2730","sourceName":"forms-embed","sourceVersion":"1.2730","sourceVersionMajor":"1","sourceVersionMinor":"2730","_debug_allPageIds":{"embedContextPageId":"99775113349","analyticsPageId":"99775113349","pageContextPageId":"99775113349"},"_debug_embedLogLines":[{"clientTimestamp":1677620692023,"level":"INFO","message":"Retrieved countryCode property from normalized embed definition response: \"DE\""},{"clientTimestamp":1677620692887,"level":"INFO","message":"Retrieved analytics values from API response which may be overriden by the embed context: {\"hutk\":\"8dcb2186cc321e828ecf3a0dd2d0cbfb\",\"canonicalUrl\":\"https://catalyst.phrma.org/icymi-cancer-death-rate-continues-to-decline-due-to-treatment-advances\",\"contentType\":\"blog-post\",\"pageId\":\"99775113349\"}"}]}"><iframe
name="target_iframe_c85fb33b-c094-4800-8f1b-1ca1630341ad_2549" style="display: none;"></iframe>
</form><form class="sign-up-form" data-hs-cf-bound="true">
<input type="hidden" name="hutk" value="">
<input type="hidden" name="mode" value="catalystSignup">
<input type="hidden" name="pageurl" value="https://qa-phrma.mrmdigital.com/">
<input type="hidden" name="pagetitle" value="PhRMA Org | PhRMA">
<div class="sign-up-input-box"><input type="email" name="email" placeholder="Enter your email address" pattern="[a-z0-9._%+-]+@[a-z0-9.-]+\.[a-z]{2,3}$" required="true" aria-label="Email Address"></div>
<div class="sign-up-submit-btn"><button type="submit" aria-label="Submit">></button></div>
</form>Text Content
* About * Policy Issues * Research & Development * Patient Support * News * Resources * Blog Sites * Innovation.org * MAT.org * PhRMA.org * About * Policy Issues * Research & Development * Patient Support * News * Resources * Blog * Sites * Innovation.org * MAT.org * PhRMA.org X SEARCH THE PHRMA NETWORK X Welcome to the future of medicine. Where together, we go boldly. LEARN MORE PPA strives to improve patient health, advance medical innovation and fuel economic growth. LEARN MORE The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development. LEARN MORE Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines. LEARN MORE Learn more about America's biopharmaceutical companies and how they seek to improve patients' lives. LEARN MORE We Work For Health aims to increase awareness by uniting workers throughout the industry. LEARN MORE Patent protection should always be considered by an inventor during the initial stages of their invention. LEARN MORE Working to spread awareness and education about the importance of secure drug disposal. LEARN MORE ABOUT PhRMA represents the country’s leading biopharmaceutical research companies and supports the search for new treatments and cures. PhRMA Commitment to Equity Industry Profile 2020 ADVOCACY From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results. 340B | PhRMA Part B | PhRMA SCIENCE Today, cutting-edge medical science is transforming patients’ lives. Discover how scientists and researchers are advancing science. The 20-year journey yielding a new weapon against cancer | PhRMA The Latest on the Biopharmaceutical Industry's Efforts to Beat Coronavirus | PhRMA PATIENTS Patient support and assistance is the top priority for PhRMA’s member companies, who are working hard to improve patients’ lives through the discovery and development of new medicines and treatments. Share the Savings | PhRMA Patient-Focused Drug Development | PhRMA RESOURCES Explore the Resource Library, the interactive State Map and the Chart Pack reports. Press Room | PhRMA Chart Packs | PhRMA ICYMI: CANCER DEATH RATE CONTINUES TO DECLINE DUE TO TREATMENT ADVANCES Matthew Norawong January 25, 2023 ICYMI: Cancer death rate continues to decline due to treatment advances. Share This Earlier this month, the American Cancer Society (ACS) released its annual report, Cancer Statistics 2023, finding the overall cancer mortality rate has declined 33% since peaking in 1991, leading to an estimated 3.8 million averted cancer deaths over this period. The report notes the continued decline in death rates since 1991, including a 1.5% decrease between 2019 and 2020 alone, increasingly reflects advances in prevention and treatment—including new medicines which have improved survival across a range of cancers. This report is the latest to document this progress. A growing body of evidence underscores the role of new medicines in recent accelerated declines in mortality across a range of cancers. One study found, between 2000 and 2016 alone, new cancer medicines were associated with nearly 1.3 million averted cancer deaths across the 15 most common tumor types. In particular, new cancer medicines were associated with nearly 130,000 prevented breast cancer deaths, nearly 400,000 prevented lung cancer deaths, and over 500,000 prevented melanoma deaths. While the ACS report highlights tremendous progress in the fight against cancer, it also reveals several alarming trends which threaten this progress and underscores the need for additional efforts to reduce health disparities and address unmet need across a range of cancers. Here are some key takeaways from the report: Major reductions in cervical cancer incidence rates among women are tied to administration of the human papillomavirus (HPV) vaccine. The first vaccine that targets two strains of HPV (HPV-16 and HPV-18) that are responsible for 70% of cervical cancers was approved for females ages nine to 26 by the U.S. Food and Drug Administration (FDA) in 2006. Among women ages 20 to 24 — the first cohort of adolescents to receive the vaccine — the incidence rate of cervical cancer dropped 65% from 2012 to 2019 compared to 33% during the previous seven-year period (2005-2012). The authors note this trend likely foreshadows declines in other HPV-associated cancers in coming years. Targeted therapies and immunotherapies are improving survival for cancer patients. For all cancers, the 5-year survival rate was 68% for diagnoses made during 2012 to 2018, up from 49% during the mid-70s. This increase is due in part to improvements in treatment, in particular the development of targeted therapies and immunotherapies, which have transformed the treatment landscape for many different types of cancer. For example, the report notes patients who were diagnosed with a certain form of leukemia and were treated with tyrosine-kinase inhibitors — a type of targeted therapy — are living near normal life spans. Similarly, a cascade of game changing immunotherapies and targeted therapies have dramatically improved survival for advanced melanoma, leading to a doubling of 3-year survival rates over the past decade and a significant decrease of the number of individuals living with this aggressive form of cancer. Likewise, the report finds overall cancer mortality declines are largely driven by lung cancer, for which mortality declines have steepened in recent years, in part due to treatment advances associated with novel therapies which have extended survival, in addition to earlier detection and other treatments. Rising incidence of advanced stage cancers which disproportionately impact certain racial groups are particularly concerning. Cases of prostate, breast and certain types of uterine cancers, all of which are associated with significant disparities in mortality among members of the African American and Black community, are on the rise according to the report. For example, incidence of prostate cancer, the second leading cause of death for men in the U.S., increased by 3% per year between 2014 and 2019 — driven primarily by increased diagnosis of advanced stages of the disease. This trend follows a nearly 2-decade decline, revealing significant gaps in screening and diagnosis which have contributed to this shift, particularly among Black men who face 70% higher incidence of prostate cancer and 2-4 times higher mortality rates relative to every other racial and ethnic group. Successful interventions are needed to reduce these inequalities and continue to accelerate progress against cancer. To continue to make progress and deliver hope to those battling cancer, the biopharmaceutical industry remains committed to researching and developing innovative medicines that will extend survival and improve the quality of life for cancer patients. Excitingly, there is a robust pipeline of medicines in development targeting various forms of cancer, including breast cancer, ovarian cancer, prostate cancer, pediatric cancer and chronic forms of leukemia and lymphoma. Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by the FDA. While the recent accelerated declines in cancer mortality and the treatment advances that have played a critical role in driving this progress are truly remarkable, significant unmet medical needs and health care inequities persist. Continued progress in the fight against cancer can only be sustained with a policy and regulatory framework that fosters this kind of innovation. That’s why it is concerning that the price setting provision of the Inflation Reduction Act (IRA) severely undercuts biopharmaceutical R&D efforts in a way that runs counter to the fight against cancer. This law will upend incentives for R&D investment, with some economists estimating that the IRA could result in 135 fewer new treatments over the next two decades. Furthermore, the IRA guts the incentives necessary to encourage investment in R&D after medicines are approved. Post-approval research paves the way for important advancements in patient care that includes expanding and discovering new uses for approved medicines. Some of the most important research on medicines, particularly for disease areas like cancer, happens after a medicine is approved. For example, nearly 60% of oncology medicines approved a decade ago received additional approvals for new indications, and most of those were seven or more years after the initial approval according to an analysis of FDA approval data conducted by Partnership for Health Analytic Research. In light of the findings of the recent ACS report, it is critical for policymakers to recognize the need for preserving an environment that allows this progress to be sustained. We will continue to educate the public and policymakers about the harm the IRA and other misguided price setting policies will do to patients, R&D and the broader health care system. And we will never stop fighting for the kind of solutions patients and our health care system need. Read more about the fight against cancer at PhRMA.org/Cancer Topics: Medicines in Development, Cancer, Drug Cost, Equity SEARCH THE CATALYST Search Now VIEW POSTS BY TOPIC * Research and Development (361) * Medicare (279) * Drug Cost (196) * Part D (195) * Out-of-Pocket Costs (166) * Medicare Monday (159) * Intellectual Property (152) * Coronavirus (142) * Cancer (126) * Patients (116) * Access (111) * Medicines in Development (109) * FDA (99) * Health Insurance (96) * Part B (86) * PhRMA Member Company (86) * Policy Solutions (85) * Let's Talk About Cost (83) * 340B (82) * Access Better Coverage (68) * Clinical Trials (68) * Affordable Care Act (66) * The Value Collaborative (66) * Vaccines (66) * Value-Driven Health Care (65) * Trade (58) * Economic Impact (55) * Patents (53) * Hospitals (49) * Adherence (47) * New Era of Medicine (47) * 340B Spotlight (46) * Polling (42) * Rare Diseases (40) * Prescription Drug Safety (38) * Diabetes (35) * Equity (35) * Proactive Agenda (35) * Alzheimer's (34) * Health Equity (34) * Pharmacy Benefit Managers (34) * Ask About Adherence (33) * HIV/AIDS (33) * PDUFA (33) * Burden on Patients (32) * Government Price Setting (32) * GoBoldly (31) * IP Explained (30) * Medicaid (30) * Hepatitis C (29) * Mental Health (28) * Biologics and Biosimilars (24) * Personalized Medicine (24) * CMMI (23) * International Reference Pricing (22) * Counterfeit Drugs (21) * Importation (21) * Infectious Diseases (20) * Value Assessment (20) * Chronic Disease (19) * High Cholesterol (19) * R&D Focus (19) * Prescription for Medicare (18) * From Hope to Cures (16) * I'm Not Average (16) * Manufacturing (16) * Multiple Sclerosis (16) * Pelosi Plan (16) * Empower Consumers (13) * FDA Modernization (13) * Heart Disease (13) * Patient Assistance Programs (13) * Antimicrobial Resistance (12) * Voters for Cures (12) * Partnership for Prescription Assistance (11) * Asthma (9) * Drug Importation (9) * PhRMA Foundation (9) * Value-Based Contracting (9) * ALS (8) * Leukemia (8) * STEM (8) * TRIPS Waiver (8) * Rheumatoid Arthritis (7) * IPAB (6) * Safe Drug Disposal (6) * Alternative Payment Models (5) * Quality Metrics (5) * Rx Drug Abuse (5) * Kidney Disease (4) * Lupus (4) * Parkinson's (4) * Word of the Month (4) * Cystic Fibrosis (3) * REMS (3) * Government Arbitration (2) * Immunotherapy (2) * Pediatrics (2) * Supply Chain (2) * Venture Capital (2) * Pandemic Preparedness (1) see all VIEW POSTS BY CONTRIBUTOR * Abigail Lore * Allyson Funk * Amber Lyons * Amey Sutkowski * Andrew Powaleny * Anjam Aziz * Anne McDonald Pritchett, PhD * Ashley Czin * Ashley Flint * Bill Chin, M.D. * Brian Newell * Brooke Ringel * Caitlin Carroll * Camille Jackson * Carolyn Ha * Chris Moore * Christian Clymer * Courtney Christian * Cynthia Hicks * David Korn * Debra DeShong * Douglas Petersen * Dr. Freda Lewis-Hall * Dr. Steven Thomas * Eileen Cannon * Emilie Signora * Emily Donaldson * Emma Van Hook * Ernest Kawka * Ernest Kawka and Douglas Petersen * Gabby Migliara * Gabriela Lavezzari * Giovanni Caforio, M.D. * Gretta Stone * Guest Contributor * Hannah Loiacono * Hannah Mooney Mack * Holly Campbell * Ieva M. Augstums * Jackie McRae * Jasmine Gossett * Jay Taylor * Jeff Francer * Jennifer Bryant * Jim C. Stansel * Jocelyn Ulrich * Joe Vandigo * John Castellani * John Corea * John Tunnell * Jonathan Kimball * Joseph Havey * Josephine Martin * Juliet Johnson * Karyn Schwartz * Katie Koziara * Katie Verb * Kelsey Lang * Kevin Haninger * Kristin Williams * Lauren DiPaola * Lauren Neves * Lindsey Seidlitz * Lori Reilly * Lucy Vereshchagina * Mark Grayson * Mark Keida * Mark Reisenauer and Stephen J. Ubl * Matthew Norawong * Megan Van Etten * Michelle Drozd * Michelle Nyman * Mike Ybarra * Mit Spears * Mollymae Metheny * Myisha Gatson * Nick McGee * Nicole Longo * Olivia Shopshear * Pete Martinez * Priscilla VanderVeer * Rachel Licata * Rachel Weissman * Randy Burkholder * Rebecca Davison * Rebecca Marklund * Reid Porter * Richard Moscicki, M.D. * Rick Smith * Robert Zirkelbach * Ryan Garofalo * Samantha Dougherty * Samantha Hinkle * Sarah K. Martin * Sarah Spurgeon * Sarah Sutton * Sascha Haverfield * Saumil Pandya and Emily Donaldson * Scott LaGanga * Setareh Samii * Stami Williams * Stephanie Fischer * Stephen J. Ubl * Stephen J. Ubl and Giovanni Caforio, M.D. * Tiffany Haverly * Tim McClung * Tina Stow * Tom Wilbur * Yolanda Hutchins VIEW POSTS BY DATE * February 2023 (7) * January 2023 (9) * December 2022 (10) * November 2022 (18) * October 2022 (15) * September 2022 (11) * August 2022 (15) * July 2022 (21) * June 2022 (12) * May 2022 (20) * April 2022 (12) * March 2022 (10) * February 2022 (16) * January 2022 (10) * December 2021 (12) * November 2021 (16) * October 2021 (17) * September 2021 (15) * August 2021 (12) * July 2021 (16) * June 2021 (14) * May 2021 (18) * April 2021 (11) * March 2021 (12) * February 2021 (12) * January 2021 (13) * December 2020 (18) * November 2020 (14) * October 2020 (21) * September 2020 (18) * August 2020 (13) * July 2020 (15) * June 2020 (11) * May 2020 (9) * April 2020 (14) * March 2020 (9) * February 2020 (10) * January 2020 (7) * December 2019 (5) * November 2019 (9) * October 2019 (15) * September 2019 (6) * August 2019 (10) * July 2019 (8) * June 2019 (13) * May 2019 (18) * April 2019 (11) * March 2019 (14) * February 2019 (16) * January 2019 (11) * December 2018 (7) * November 2018 (3) * October 2018 (10) * September 2018 (12) * August 2018 (9) * July 2018 (9) * June 2018 (12) * May 2018 (16) * April 2018 (10) * March 2018 (13) * February 2018 (8) * January 2018 (10) * December 2017 (5) * November 2017 (10) * October 2017 (13) * September 2017 (10) * August 2017 (8) * July 2017 (19) * June 2017 (20) * May 2017 (24) * April 2017 (19) * March 2017 (18) * February 2017 (23) * January 2017 (12) * December 2016 (8) * November 2016 (12) * October 2016 (16) * September 2016 (22) * August 2016 (24) * July 2016 (17) * June 2016 (21) * May 2016 (27) * April 2016 (32) * March 2016 (26) * February 2016 (26) * January 2016 (14) * December 2015 (30) * November 2015 (29) * October 2015 (34) * September 2015 (33) * August 2015 (29) * July 2015 (34) * June 2015 (29) * May 2015 (33) * April 2015 (42) * March 2015 (33) * February 2015 (17) * January 2015 (13) * December 2014 (8) * November 2014 (15) * October 2014 (22) * September 2014 (5) * August 2014 (5) * July 2014 (9) * June 2014 (8) * May 2014 (2) * April 2014 (1) * March 2014 (1) * February 2014 (2) * January 2014 (2) * October 2013 (1) * June 2013 (1) * May 2013 (1) * April 2013 (1) * March 2013 (1) * January 2013 (1) * July 2012 (1) * June 2012 (1) * March 2011 (25) * February 2011 (31) see all VIEW POSTS BY SERIES * Ask about Adherence (33) * Medicare Monday (100) * 340B Spotlight (46) * Cost & Consequence (0) SUBSCRIBE TO EMAIL UPDATES Business Email*Many free email providers not supported (ie yahoo, hotmail, etc) First Name* Last Name* About You*Which persona best represents you? - Please Select -Employed in the BioPharmaceutical Industrygeneral publicwork in health care (non-biopharma)patientcaregiver or patient organizationgovernment or regulatory agencycredentialed news mediapr/ga/consultanteducationalInvestor/Analyst /Financial Notification Frequency*How often would you like to receive updates * Monthly * Weekly * Instant * Daily Postal Code* Lifecycle Stage STAY CONNECTED > SHARE * * * * TRENDING POSTS TRENDING POSTS * Executive order threatens R&D when we need it most to fight COVID-19 * The impact of monoclonal antibodies and COVID-19 recovery * What you need to know about newly authorized COVID-19 antiviral treatments * * * * * Members Site * Contact Us * Privacy Policy * Terms of Service * Site Map Pharmaceutical Research and Manufacturers of America® 950 F Street, NW Suite 300, Washington, DC 20004 Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review "1. Information Collection."